Allergan plans to develop and commercialize Editas Medicine’s CRISPR genome editing treatment candidate EDIT-101 globally for Leber Congenital Amaurosis type 10 (LCA10), a development effort that could generate up to $40 million for Editas.
Editas has already received $15 million after a wholly-owned Allergan subsidiary, Allergan Pharmaceuticals, exercised its option to develop and commercialize EDIT-101—an option held under a strategic alliance and option agreement between the companies inked last year.
Editas is also eligible for an additional $25 million from Allergan upon FDA acceptance of an investigational new drug (IND) application for EDIT-101.
EDIT-101 is designed to eliminate a mutation in the CEP290 gene by using CRISPR to cut out that nucleotide and surrounding DNA, thus restoring normal protein expression and function of remaining photoreceptor cells. Editas reasons that therapeutic approaches aimed at restoring function of remaining photoreceptor cells could arrest further loss of vision for ...